Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


VIB and AlgoNomics to address protein immunogenicity
AlgoNomics to expand its Epibase immunogenicity screening services with VIB screening technology.

Ghent, Belgium – December 11, 2006 - VIB and AlgoNomics NV today announced they will join forces for the immunogenicity screening of protein therapeutics. AlgoNomics will integrate the experimental know-how of the VIB into its Epibase® platform, thus creating a new, standardized platform to address T-cell driven immunogenicity.

According to Dr. Rudy Dekeyser, Director Tech Transfer of VIB: “A pilot collaboration prior to this agreement surfaced the significant added value of combining VIB’s knowhow
with AlgoNomics’ expertise. VIB is therefore pleased to extend its partnership with AlgoNomics, a leading company in the field of T-cell epitope identification”.

The combination of AlgoNomics in silico T-cell epitope identification platform Epibase® with VIB’s know-how in the in vitro characterization of T-cell activation by those epitopes generates a new and standardized platform to address T-cell driven immunogenicity.

'Through this collaboration, we were able to develop an immunogenicity screening assay that combines sensitivity with reliability, and could give direct estimates of the frequency of reactive T-lymphocytes', comments Prof. Dr. Johan Grooten, Head of the VIB laboratory for Molecular Immunology.

Dr. Ignace Lasters, Chief Executive Officer of AlgoNomics commented: 'We are delighted to be working with the research team of the VIB, and to merge their know-how in immunology and immunogenicity with our Epibase® platform. By expanding our immunogenicity testing and -monitoring pipeline, we illustrate our commitment to provide first-in-class services for the development of optimized protein therapeutics. ' Financial terms of the collaboration were not disclosed.

About VIB
VIB, the Flanders Interuniversity Institute for Biotechnology, is a research institute where 900 scientists conduct gene technological research in a number of life-science domains, such as human health care and plant systems biology. Through a joint venture with four Flemish universities (Ghent University, the Katholieke Universiteit Leuven, the University of Antwerp, and the Vrije Universiteit Brussel) and a solid funding program for strategic basic research, VIB unites the forces of nine university science departments in a single institute. Through its technology transfer activities, VIB strives to convert the research results into products for the benefit of consumers and patients. VIB also distributes scientifically substantiated information about all aspects of biotechnology to a broad public. For more information about VIB visit

About AlgoNomics NV
AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions.

AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups, widely applied in the discovery of vaccines and therapeutic proteins. For more information about AlgoNomics visit

About Epibase®
Epibase® is AlgoNomics’ proprietary platform for T-cell epitope identification. This epitope discovery is applied to vaccine development in the cancer and infectious diseases field, as well as to protein epitope profiling and Immunotuning®.

The uniqueness of Epibase® resides in its capability to identify the T-cell epitopes for any collection of proteins from any biological source (viral, cancer or other), for all HLA types covering most of the human population. The approach allows to document and optimize leads such as vaccines and therapeutic proteins for any specific population.z

Unlike learning-based methods, Epibase® can identify epitopes for those HLA sub-types for which little or no experimental data is available. In addi

Publisher Contact Information:


Company profile of AlgoNomics (acquired by Lonza Group)
Past press releases of AlgoNomics (acquired by Lonza Group).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Sep 13N/AWireless services
Sep 11€0.3MInternet services
Sep 10€25.0MBiopharmaceuticals
Sep 10N/AInternet services
Sep 10€25.0MBiotechnology
Sep 10€1,700.0MGames

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.